Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[History of interventional cardiology].

Orvosi hetilap·2026
Same author

[Balloon pulmonary angioplasty in Gottsegen National Cardiovascular Center - results of the first 2 years].

Orvosi hetilap·2026
Same author

[TricValve implantation: new catheter intervention in severe tricuspid regurgitation].

Orvosi hetilap·2025
Same author

Long-Term Outcome of Unprotected Left Main Percutaneous Coronary Interventions-An 8-Year Single-Tertiary-Care-Center Experience.

Journal of personalized medicine·2025
Same author

Midterm Outcome of Balloon-Expandable Covered Stenting of Femoral Access Site Complications.

Journal of clinical medicine·2024
Same author

First application of the distal radial approach for severe mechanical surgical aortic valve paravalvular leak transcatheter closure with a double vascular plug: a case report.

European heart journal. Case reports·2024

Related Experiment Video

Updated: Jul 17, 2026

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease
06:39

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Published on: February 18, 2020

[Drug-eluting coronary stents].

Géza Fontos1

  • 1Gottsegen György Országos Kardiológiai Intézet, Hemodinamikai Osztály, Budapest.

Orvosi Hetilap
|February 15, 2007
PubMed
Summary

Coronary stents have evolved significantly, improving treatment for coronary artery disease. Drug-eluting stents now dramatically reduce in-stent restenosis, a major limitation of percutaneous coronary intervention.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomedical Engineering

Background:

  • Percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass grafting (CABG) are established treatments for coronary artery disease (CAD).
  • The introduction of coronary stents revolutionized PCI by addressing limitations of early angioplasty techniques.
  • Early coronary stents faced challenges including subacute thrombosis and bleeding complications, limiting their use to specific situations like failed PTCA.

Purpose of the Study:

  • To review the historical development and evolution of coronary stent technology.
  • To highlight the impact of stent implantation on managing coronary artery disease.
  • To discuss the challenges of in-stent restenosis and the advancements offered by drug-eluting stents.

Main Methods:

Related Experiment Videos

Last Updated: Jul 17, 2026

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease
06:39

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Published on: February 18, 2020

  • Historical review of key milestones in interventional cardiology, focusing on stent development.
  • Analysis of clinical trial data (e.g., BENESTENT, STRESS) demonstrating the efficacy of elective stenting.
  • Examination of the impact of therapeutic advancements like dual antiplatelet therapy and high-pressure implantation.

Main Results:

  • Early percutaneous interventions evolved from simple balloon angioplasty to the use of stents to cover intimal flaps and prevent elastic recoil.
  • Elective stent implantation significantly reduced restenosis rates, as shown by major clinical trials.
  • Drug-eluting stents have dramatically decreased the incidence of in-stent restenosis to below 10%, overcoming a major limitation of bare-metal stents.

Conclusions:

  • Coronary stent technology has undergone revolutionary advancements, transforming CAD treatment.
  • In-stent restenosis remains a significant challenge in PCI, though greatly mitigated by drug-eluting stents.
  • Ongoing innovation in interventional cardiology continues to improve outcomes for patients with coronary artery disease.